{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:00Z","timestamp":1786987020622,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["RC-2024-2790083"],"award-info":[{"award-number":["RC-2024-2790083"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.02.015","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T03:24:25Z","timestamp":1741058665000},"page":"e524-e532.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Morsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Elli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3200-9654","authenticated-orcid":false,"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Beggiato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-9028","authenticated-orcid":false,"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tieghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8290-1253","authenticated-orcid":false,"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-9229","authenticated-orcid":false,"given":"Alessandro","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Dedola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto M.","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cilloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Branzanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.clml.2025.02.015_bib0001","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.02.015_bib0002","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cam4.136","article-title":"Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review","volume":"2","author":"Mitra","year":"2013","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.clml.2025.02.015_bib0003","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00277-024-05704-0","article-title":"Ruxolitinib adherence in myelofibrosis and Polycythemia Vera: the \u201cRAMP\u201d Italian multicenter prospective study","volume":"103","author":"Palandri","year":"2024","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.02.015_bib0004","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.02.015_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.02.015_bib0006","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fon-2022-1298","article-title":"Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study","volume":"19","author":"Mascarenhas","year":"2023","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.02.015_bib0007","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2025.02.015_bib0008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.clml.2025.02.015_bib0009","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/14656566.2023.2213435","article-title":"Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy","volume":"24","author":"Bose","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.clml.2025.02.015_bib0010","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of Fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.02.015_bib0011","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.02.015_bib0012","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/bjh.19654","article-title":"Ruxolitinib after fedratinib failure in patients with myelofibrosis: a real-world case series","volume":"205","author":"Palandri","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.02.015_bib0013","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.3324\/haematol.2022.282612","article-title":"Momelotinib (JAK1\/JAK2\/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis","volume":"108","author":"Tefferi","year":"2023","journal-title":"Haematologica"},{"issue":"34","key":"10.1016\/j.clml.2025.02.015_bib0014","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of Momelotinib versus Ruxolitinib in Janus Kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.02.015_bib0015","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.02.015_bib0016","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17474086.2022.2112565","article-title":"Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia","volume":"15","author":"Mascarenhas","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.015_bib0017","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"32","key":"10.1016\/j.clml.2025.02.015_bib0018","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: pelabresib in combination with Ruxolitinib for Janus kinase inhibitor treatment-na\u00efve myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"37","key":"10.1016\/j.clml.2025.02.015_bib0019","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.2217\/fon-2022-0901","article-title":"BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed\/refractory myelofibrosis","volume":"18","author":"Verstovsek","year":"2022","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.02.015_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100010","article-title":"A novel application of XPO1 inhibition for the treatment of myelofibrosis","volume":"1","author":"Metzger","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.015_bib0021","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood-2024-201729","article-title":"Hematological improvement and other clinical benefits of Elritercept As monotherapy and in combination with Ruxolitinib in participants with myelofibrosis from the ongoing phase 2 restore trial","volume":"144","author":"Harrison","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2025.02.015_bib0022","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.clml.2025.02.015_bib0023","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: international Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.02.015_bib0024","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.02.015_bib0025","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2025.02.015_bib0026","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/modpathol.2012.87","article-title":"The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis","volume":"25","author":"Gianelli","year":"2012","journal-title":"Modern Pathol"},{"issue":"4","key":"10.1016\/j.clml.2025.02.015_bib0027","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.clml.2025.02.015_bib0028","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.02.015_bib0029","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.02.015_bib0030","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00277-023-05126-4","article-title":"How I manage anemia related to myelofibrosis and its treatment regimens","volume":"102","author":"Verstovsek","year":"2023","journal-title":"Ann Hematol"},{"issue":"45","key":"10.1016\/j.clml.2025.02.015_bib0031","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.clml.2025.02.015_bib0032","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/ijms19030898","article-title":"Understanding Splenomegaly in myelofibrosis: association with molecular pathogenesis","volume":"19","author":"Song","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clml.2025.02.015_bib0033","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.clml.2025.02.015_bib0034","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2025.02.015_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00713-6","article-title":"Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis","volume":"12","author":"Coltro","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2025.02.015_bib0036","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.02.015_bib0037","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jha2.745","article-title":"Incidence of blast phase in myelofibrosis according to anemia severity","volume":"4","author":"Mora","year":"2023","journal-title":"EJHaem"},{"issue":"8","key":"10.1016\/j.clml.2025.02.015_bib0038","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/cncr.35156","article-title":"Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy","volume":"130","author":"Palandri","year":"2024","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2025.02.015_bib0039","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2025.02.015_bib0040","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-020-04069-4","article-title":"Modern management of splenomegaly in patients with myelofibrosis","volume":"99","author":"Tremblay","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.015_bib0041","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjh.19812","article-title":"The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: a prospective real-world study on AIFA monitoring registries","volume":"206","author":"Breccia","year":"2025","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.02.015_bib0042","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:18Z","timestamp":1762600638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000771"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}